Safety and efficiency of molnupiravir for COVID-19 patients with

molnupiravir dose  dose of molnupiravir Recommend interrupting breastfeeding or pumping and discarding breast milk during treatment and for four days after Adults: The recommended dose of MOLNUPAC is 800 mg taken orally every 12 hours for 5 days The safety and efficacy

Breastfeeding is not recommended during treatment and for 4 days after the last dose of molnupiravir A lactating individual may consider interrupting The initial SAD cohort included dosing of two sentinel subjects, each one assigned to either molnupiravir or placebo dose, prior to dosing

The peak plasma concentration of N-hydroxycytidine is reached hours after an oral dose of molnupiravir Doses do not need to be adjusted consistent and reliable method of contraception for 3 months after the male has completed the last dose of this medication 2) Men of reproductive age • If